Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Venetoclax combination therapies in AML

Andrew Wei, MBBS, PhD, of Alfred Hospital and Monash University, Melbourne, Australia, discusses viable options for combining venetoclax with targeted therapies in acute myeloid leukemia (AML). Specifically outlined is venetoclax combined with ivosidenib, an IDH1 inhibitor, as well as with gilteritinib, a FLT3 inhibitor. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).